Hyderabad: A 29 to 50 per cent reduction in the risk of probable stent thrombosis has been reported with the use of the Indian Yukon Choice PC stent as compared to American stents.
The stent was earlier imported from Germany and the manufacturer set up its unit in Dehradun from where the stent is being produced for the last five years.
This drug eluting stent is used in the Aarogyasri scheme of the TS and AP governments. It is priced at Rs 20,000 per stent in India. The finding regarding the stent was reported at the scientific session of the American Heart Association.
Dr Syed Immamuddin, professor of cardiology at the Osmania Medical College, said that there were challenges presented with the stents earlier. “They these have now seen major improvements. Along with the improvements in the stents, there has also been increased operating experience by cardiologists which is adding to the benefit.”
The randomised control trial presented data of 10 years to the scientific session. Yukon Choice PC is produced by an Indian manufacturer Translumina Therapeutics LLP and is approved for use in India.
The paper was presented in the American Heart Association so that it can be approved for use in America and Europe. The randomised control trial of the stent was carried out at the German Heart Centre, Munich, by Dr Sebastian Kufner.
This is for the first time that a decade-long research data has been presented for efficacy and safety of drug eluting stents. The data presented for stents earlier was only for five years.
Dr Sebastian Kufner in his presentation stated that Yukon Choice PC DES would give long-term success to the procedure of angioplasty. The risk of stent-related major cardiac events in terms of thrombosis has been recorded in the stents. Stent thrombosis is when a blood clot forms in the stent leading to adverse cardiac event and can be fatal too.
In the data comparison with the existing American stents in the market it was found that the adverse risk of cardiac arrest was reduced by 29 per cent in one stent and 50 per cent in another stent. Yukon Choice PC is using a combination of special surface modification and low polymeric load for optimal release of anti-proliferative drugs due to which there is durable performance of the device.
The success of this trial will increase the confidence of cardiologists in using new generation drug eluting stents and also reassure patients according to the research paper which was published in the journal Circulation.
